The Challenge of Liver toxicity in drug development:
Early and Accurate Detection of Liver Toxicity across development stages.
Annual cost to Pharma due to late-stage toxicity failures.
DILI is the leading cause of acute liver failure worldwide.
Medications currently linked to liver injury and attrition.
People in the US taking hepatotoxic drugs needing monitoring.
Testing Limitations: Traditional indicators like ALT/AST lack specificity and are often released by non-hepatic tissues (muscle, heart), leading to false safety flags.
LiverAce™ SinglePlex Kit
Accurate PCR-free miRNA-122 detection
miRNA-122 is well established as an early biomarker for drug-induced liver toxicity from liver organoids, across small and large animal species and in humans. miRNA-122 rises much earlier and is more liver specific than traditional enzymes, such as AST/ALT, providing the high specificity required to eliminate false toxicity flags. By overcoming the miRNA degradation to isomers challenge that plagues the use of PCR for miRNAs, LiverAce™ SinglePlex delivers the “Fail-Fast” precision required for confident drug development.
For Research Use Only
Not for use in diagnostic procedures
Complete drug development process
One assay for the complete drug development process. Provides accurate and reproducible assessment of drug toxicity across all stages, identifying problems early in the development lifecycle.
Diagnostic Sensitivity
Key Values
Scientific Proof
Key Publications (Biomarkers)
Clinical evidence supporting miR-122 as a superior liver injury biomarker.
Desina Chemistry (DGL-Tech)
Foundational papers on the Destina Chemistry that powers LiverAce™ assays.
Product Characteristics
Kit Specifications
| Parameter | Value |
|---|---|
| Analytes | miRNA-122 |
| Platform | Luminex xMAP® (MAGPIX®, FLEXMAP 3D®, etc.) |
| Detection Method | PCR-Free Destina Chemistry |
| Time to Result | < 5 Hours |
| Sample Volume | 25 µL |
| Sample Type | Serum, Plasma |
| Quantification Range | Absolute (Calibrators included) |
Performance Characteristics
Assay Sensitivity
| Analyte | LOD (pg/mL) | LLOQ (pg/mL) |
|---|---|---|
| miR-122 | 2.4 | 21 |
Precision
| Analyte | Intra %CV | Inter %CV |
|---|---|---|
| miR-122 | < 10% | < 20% |
Assay Procedure
Simple, Streamlined, Superior
1. Add Sample
2. Hybridizing
3. Label
4. Read
Applications & Research Fields
- Pharma R&D & Drug Development
- CROs & Service Labs
- Preclinical Safety Assessment
- Liver Toxicity (DILI) Screening
Documentation
Files are available upon request to ensure you receive the latest version.
Ready to Transform Your Liver Safety Assessment?
Our specialists are ready to discuss your testing needs.
Get in Touch